The Keenova-sponsored study re-examined data from the IMPRESS I and II clinical trials to determine if baseline penile pain influences outcomes for men treated with XIAFLEX (collagenase clostridium histolyticum). Researchers concluded that while pain and the duration of the disease are relevant, they should not serve as the exclusive determinants for when a patient begins therapy.

Landon Trost, director of the Male Fertility and Peyronie's Clinic in Orem, Utah, and senior author of the paper, emphasized that clinicians must look beyond localized discomfort. He noted that treatment decisions should be grounded in a broader clinical assessment and a current understanding of how the condition evolves. Peyronie’s disease, which involves the buildup of fibrous scar tissue and subsequent curvature deformity, affects an estimated 1 in 10 men in the United States, though many remain undiagnosed due to the sensitive nature of the condition.